Fig 1: Downregulation of CDCA7L inhibits glioma cell growth in vivo. (A) The images of mice implanted with intracranial tumors formed by U87 on days 3 and 8. (B) Ki-67 in tumors derived from U87 cells following transfection with CDCA7L siRNA or NC siRNA examined by immunohistochemistry. Scale bar, 100 µm. (C) Downregulation CDCA7L expression reduced the CCND1 expression level in vivo shown by western blot analysis. *P<0.05 indicates statistical significance compared with the NC siRNA group. (D) Kaplan-Meier curves plotted to measure the overall survival in the 2 ×enograft groups. CDCA7L, cell division cycle-associated 7 like; NC, negative control.
Fig 2: CDCA7L siRNA was constructed and transfected into the glioma U87 cells. (A) RT-qPCR was performed to detect the CDCA7L mRNA expression levels in glioma cell lines. (B) Infection efficiency was examined by fluorescence microscopy at 72 h following infection. Scale bar, 100 µm. (C and D) The knockdown efficiency of CDCA7L siRNA was assessed by (C) RT-qPCR assay and (D) western blot analysis. *P<0.05 indicates statistical significance compared with the control group. CDCA7L, cell division cycle-associated 7 like; NC, negative control.
Fig 3: CDCA7L expression profiles and prognostic value in glioma. (A) CDCA7L expression levels were evidently higher in GBM tissues compared with those in LGG tissues in the OncoLnc dataset. (B) Higher CDCA7L expression is associated with a shorter OS of glioma patients. (C) CDCA7L expression levels were markedly higher in GBM tissues relative to those in NBTs from the Oncomine dataset. (D and E) CDCA7L mRNA and protein expression levels in glioma samples and NBTs. *P<0.05 indicates statistical significance compared with the NBTs group. CDCA7L, cell division cycle-associated 7 like; GBM, glioblastoma; LGG, low-grade glioma; NBTs, normal brain tissues; OS, overall survival.
Fig 4: CDCA7L modulates the U87 glioma cell cycle, apoptosis and invasion. (A and B) Flow cytometric analysis of (A) cell cycle distribution and (B) apoptosis of U87 cells transfected with CDCA7L siRNA or NC siRNA. (C) Downregulation of CDCA7L expression reduced the number of invading cells. Scale bar, 20 µm. *P<0.05 indicates statistical significance compared with the NC siRNA group. CDCA7L, cell division cycle-associated 7 like; NC, negative control.
Fig 5: Downregulation of CDCA7L inhibits glioma cell proliferation and colony formation. (A) CCK-8 assay showing that the inhibition of CDCA7L decreased the proliferation of U87 glioma cells. (B) Colony formation was also significantly reduced following CDCA7L downregulation. (C) EdU assays indicating that the downregulation of CDCA7L inhibited the proliferation of U87 glioma cells. Scale bar, 100 µm. *P<0.05 indicates statistical significance compared with the NC siRNA group. CDCA7L, cell division cycle-associated 7 like; NC, negative control.
Supplier Page from Abcam for Anti-CDCA7L/HR1 antibody